Aspirin is the gold standard for antiplatelet therapy. And a daily low-dose aspirin is prescribed widely for the prevention of cardiovascular disease. Now, a new study suggests that common genetic variation in the gene for catechol-O-methyltransferase (COMT) may modify the cardiovascular benefit of aspirin, and in some people, may confer slight harm. The findings, led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and Brigham and Women's Hospital ...
via Medindia Health News More READ
via Medindia Health News More READ
No comments:
Post a Comment